Insider · CIK 0001691102

Yea Christopher

Reports to the SEC for 1 company · FRAMINGHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001691102

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-11	KalVista Pharmaceuticals, Inc.D Disposition to Issuer	CHIEF DEVELOPMENT OFFICER	DDisposition to Issuer	−230K sh	—	—	0
2026-06-11	KalVista Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF DEVELOPMENT OFFICER	DDisposition to Issuer	−53.5K sh	—	—	0
2026-06-11	KalVista Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF DEVELOPMENT OFFICER	DDisposition to Issuer	−52.6K sh	—	—	0
2026-06-11	KalVista Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF DEVELOPMENT OFFICER	DDisposition to Issuer	−27.9K sh	—	—	0
2026-06-11	KalVista Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF DEVELOPMENT OFFICER	DDisposition to Issuer	−60K sh	—	—	0
2026-06-11	KalVista Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF DEVELOPMENT OFFICER	DDisposition to Issuer	−31K sh	—	—	0
2026-06-11	KalVista Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF DEVELOPMENT OFFICER	DDisposition to Issuer	−20K sh	—	—	0
2026-06-11	KalVista Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF DEVELOPMENT OFFICER	DDisposition to Issuer	−18.9K sh	—	—	0
2026-06-11	KalVista Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF DEVELOPMENT OFFICER	DDisposition to Issuer	−80K sh	—	—	0
2026-06-11	KalVista Pharmaceuticals, Inc.Restricted Stock UnitD Disposition to Issuer	CHIEF DEVELOPMENT OFFICER	DDisposition to Issuer	−25K sh	—	—	0
2026-06-11	KalVista Pharmaceuticals, Inc.Restricted Stock UnitD Disposition to Issuer	CHIEF DEVELOPMENT OFFICER	DDisposition to Issuer	−41.3K sh	—	—	0
2026-05-27	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+33.8K sh	$7.07	+$239K	263,718
2026-05-27	KalVista Pharmaceuticals, Inc.S Sale	CHIEF DEVELOPMENT OFFICER	SSale	−33.8K sh	$26.78	−$905K	229,918
2026-05-27	KalVista Pharmaceuticals, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−33.8K sh	—	—	0
2026-05-26	KalVista Pharmaceuticals, Inc.S Sale	CHIEF DEVELOPMENT OFFICER	SSale	−1,966 sh	$26.78	−$52.6K	229,918
2026-05-22	KalVista Pharmaceuticals, Inc.S Sale	CHIEF DEVELOPMENT OFFICER	SSale	−2,358 sh	$26.78	−$63.2K	228,759
2026-05-22	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+3,125 sh	—	—	231,884
2026-05-22	KalVista Pharmaceuticals, Inc.Restricted Stock UnitM Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−3,125 sh	—	—	25,000
2026-05-21	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+3,750 sh	—	—	231,117
2026-05-21	KalVista Pharmaceuticals, Inc.Restricted Stock UnitM Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−3,750 sh	—	—	41,250
2026-05-18	KalVista Pharmaceuticals, Inc.S Sale	CHIEF DEVELOPMENT OFFICER	SSale	−1,108 sh	$26.76	−$29.7K	227,367
2026-05-17	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+1,774 sh	—	—	228,475
2026-05-17	KalVista Pharmaceuticals, Inc.Restricted Stock UnitM Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−1,774 sh	—	—	0
2026-02-23	KalVista Pharmaceuticals, Inc.S Sale	CHIEF DEVELOPMENT OFFICER	SSale	−4,347 sh	$15.57	−$67.7K	226,701
2026-02-22	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+3,125 sh	—	—	231,048
2026-02-22	KalVista Pharmaceuticals, Inc.Restricted Stock UnitM Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−3,125 sh	—	—	28,125
2026-02-21	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+3,750 sh	—	—	227,923
2026-02-21	KalVista Pharmaceuticals, Inc.Restricted Stock UnitM Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−3,750 sh	—	—	45,000
2026-02-18	KalVista Pharmaceuticals, Inc.S Sale	CHIEF DEVELOPMENT OFFICER	SSale	−1,109 sh	$15.00	−$16.6K	224,173
2026-02-17	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+1,774 sh	—	—	225,282
2026-02-17	KalVista Pharmaceuticals, Inc.Restricted Stock UnitM Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−1,774 sh	—	—	1,774
2025-11-24	KalVista Pharmaceuticals, Inc.S Sale	CHIEF DEVELOPMENT OFFICER	SSale	−4,331 sh	$13.45	−$58.3K	223,508
2025-11-22	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+3,125 sh	—	—	227,839
2025-11-22	KalVista Pharmaceuticals, Inc.Restricted Stock UnitM Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−3,125 sh	—	—	31,250
2025-11-21	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+3,750 sh	—	—	224,714
2025-11-21	KalVista Pharmaceuticals, Inc.Restricted Stock UnitM Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−3,750 sh	—	—	48,750
2025-11-20	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+87.4K sh	$0.00	+$375.777	220,964
2025-11-20	KalVista Pharmaceuticals, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−87.4K sh	—	—	0
2025-11-18	KalVista Pharmaceuticals, Inc.S Sale	CHIEF DEVELOPMENT OFFICER	SSale	−2,683 sh	$14.48	−$38.8K	133,574
2025-11-17	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+4,205 sh	—	—	136,257
2025-11-17	KalVista Pharmaceuticals, Inc.Restricted Stock UnitM Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−1,774 sh	—	—	3,548
2025-11-17	KalVista Pharmaceuticals, Inc.Restricted Stock UnitM Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−2,431 sh	—	—	0
2025-08-25	KalVista Pharmaceuticals, Inc.S Sale	CHIEF DEVELOPMENT OFFICER	SSale	−1,954 sh	$13.42	−$26.2K	132,052
2025-08-22	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+3,125 sh	—	—	134,006
2025-08-22	KalVista Pharmaceuticals, Inc.Restricted Stock UnitM Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−3,125 sh	—	—	34,375
2025-08-22	KalVista Pharmaceuticals, Inc.S Sale	CHIEF DEVELOPMENT OFFICER	SSale	−2,362 sh	$13.22	−$31.2K	130,881
2025-08-21	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+3,750 sh	—	—	133,243
2025-08-21	KalVista Pharmaceuticals, Inc.Restricted Stock UnitM Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	−3,750 sh	—	—	52,500
2025-08-18	KalVista Pharmaceuticals, Inc.S Sale	CHIEF DEVELOPMENT OFFICER	SSale	−2,649 sh	$13.19	−$34.9K	129,493
2025-08-17	KalVista Pharmaceuticals, Inc.M Exercise/Conversion	CHIEF DEVELOPMENT OFFICER	MExercise/Conversion	+4,203 sh	—	—	132,142

Recent filings

Accepted (ET)
Jun 114
Yea Christopher0001691102-26-000009
SEC(opens sec.gov)
May 294
Yea Christopher0001691102-26-000007
SEC(opens sec.gov)
May 274
Yea Christopher0001691102-26-000006
SEC(opens sec.gov)
May 264
Yea Christopher0001691102-26-000005
SEC(opens sec.gov)

Companies

KalVista Pharmaceuticals, Inc.CHIEF DEVELOPMENT OFFICER

Address

C/O KALVISTA PHARMACEUTICALS, INC. 200 CROSSING BOULEVARD

FRAMINGHAM, MA, 01702